Discordant humoral and t-cell response to mrna sars-cov-2 vaccine and the risk of breakthrough infections in women with breast cancer, receiving cyclin-dependent kinase 4 and 6 inhibitors

HIGHLIGHTS

• who: Cristina Saavedra and colleagues from the University Hospital, Madrid, Spain have published the research work: Discordant Humoral and T-Cell Response to mRNA SARS-CoV-2 Vaccine and the Risk of Breakthrough Infections in Women with Breast Cancer, Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors, in the Journal: Cancers 2023, 15, x FOR PEER REVIEW of /2023/
• what: The authors report the results of patients undergoing treatment with CDK4/6i, and compare these data with the results obtained in a matched cohort of healthcare workers (HCW). The study was approved by the institutional . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.